Literature DB >> 22722952

Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy.

Laura Galli1, Stefania Salpietro, Gabriele Pellicciotta, Alberto Galliani, Piermarco Piatti, Hamid Hasson, Monica Guffanti, Nicola Gianotti, Alba Bigoloni, Adriano Lazzarin, Antonella Castagna.   

Abstract

Type 2 diabetes mellitus is a growing problem in HIV population and a comparison with the general population may help screening and prevention. In this cross-sectional study the authors determined the prevalence of type 2 diabetes mellitus in 4,249 HIV-infected subjects attending the San Raffaele Infectious Diseases Department compared with 9,148 healthy controls recruited in 15 Italian regions, and identified risk factors associated with of type 2 diabetes mellitus. Type 2 diabetes mellitus was defined as reported diabetes, a fasting plasma glucose concentration ≥7.0 mmol/l, or current use of anti-diabetic medication. Prevalence of type 2 diabetes mellitus was higher in HIV-infected than healthy subjects (4.1 vs. 2.5 %; P < 0.0001). At multivariable analysis, HIV-infected subjects (odds ratio 1.70, 95 % CI, 1.12-2.51; P = 0.009), older age (P < 0.0001), higher BMI (P < 0.0001) and hypertension (P = 0.039) were associated with a higher risk of diabetes. Among HIV-infected patients, the risk of type 2 diabetes mellitus increased with older age (P < 0.0001), higher BMI (P = 0.003), higher triglycerides (P = 0.015) lower total cholesterol (P = 0.008), longer duration of HIV infection (P = 0.036) lower nadir CD4 (P = 0.027). Prevalence of type 2 diabetes mellitus in HIV-infected subjects was almost two-fold increased than healthy subjects and it was associated with the typical risk factors of the general population and also to longer duration of HIV infection and lower nadir CD4.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22722952     DOI: 10.1007/s10654-012-9707-5

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  26 in total

1.  Abacavir and diabetes.

Authors:  G A Modest; J Fuller
Journal:  N Engl J Med       Date:  2001-01-11       Impact factor: 91.245

2.  A comparison of factors associated with prevalent diabetes mellitus among HIV-Infected antiretroviral-naive individuals versus individuals in the National Health and Nutritional Examination Survey cohort.

Authors:  Indira Brar; Jonathan Shuter; Avis Thomas; Eric Daniels; Judith Absalon
Journal:  J Acquir Immune Defic Syndr       Date:  2007-05-01       Impact factor: 3.731

Review 3.  Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis.

Authors:  Francesco Sofi; Rosanna Abbate; Gian Franco Gensini; Alessandro Casini
Journal:  Am J Clin Nutr       Date:  2010-09-01       Impact factor: 7.045

4.  Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study.

Authors:  Todd T Brown; Xiuhong Li; Stephen R Cole; Lawrence A Kingsley; Frank J Palella; Sharon A Riddler; Joan S Chmiel; Barbara R Visscher; Joseph B Margolick; Adrian S Dobs
Journal:  AIDS       Date:  2005-09-02       Impact factor: 4.177

5.  HIV infection and the risk of diabetes mellitus.

Authors:  Adeel A Butt; Kathleen McGinnis; Maria C Rodriguez-Barradas; Stephen Crystal; Michael Simberkoff; Matthew Bidwell Goetz; David Leaf; Amy C Justice
Journal:  AIDS       Date:  2009-06-19       Impact factor: 4.177

6.  Diabetes trends in hospitalized HIV-infected persons in the United States, 1994-2004.

Authors:  Athena P Kourtis; Pooja Bansil; Henry S Kahn; Samuel F Posner; Denise J Jamieson
Journal:  Curr HIV Res       Date:  2009-09       Impact factor: 1.581

7.  Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.

Authors:  Handan Wand; Alexandra Calmy; Dianne L Carey; Katherine Samaras; Andrew Carr; Matthew G Law; David A Cooper; Sean Emery
Journal:  AIDS       Date:  2007-11-30       Impact factor: 4.177

8.  Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity?

Authors:  Joseph L Goulet; Shawn L Fultz; David Rimland; Adeel Butt; Cynthia Gibert; Maria Rodriguez-Barradas; Kendall Bryant; Amy C Justice
Journal:  Clin Infect Dis       Date:  2007-12-15       Impact factor: 9.079

9.  Socio-economic differences in the prevalence of diabetes in Italy: the population-based Turin study.

Authors:  Roberto Gnavi; Ludmila Karaghiosoff; Giuseppe Costa; Franco Merletti; Graziella Bruno
Journal:  Nutr Metab Cardiovasc Dis       Date:  2008-04-18       Impact factor: 4.222

10.  Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.

Authors:  Stephane De Wit; Caroline A Sabin; Rainer Weber; Signe Westring Worm; Peter Reiss; Charles Cazanave; Wafaa El-Sadr; Antonella d'Arminio Monforte; Eric Fontas; Matthew G Law; Nina Friis-Møller; Andrew Phillips
Journal:  Diabetes Care       Date:  2008-02-11       Impact factor: 17.152

View more
  39 in total

1.  Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis.

Authors:  Lesley S Park; Raúl U Hernández-Ramírez; Michael J Silverberg; Kristina Crothers; Robert Dubrow
Journal:  AIDS       Date:  2016-01       Impact factor: 4.177

Review 2.  Endocrinological aspects of HIV infection.

Authors:  F S Mirza; P Luthra; L Chirch
Journal:  J Endocrinol Invest       Date:  2018-01-08       Impact factor: 4.256

3.  The Rotterdam Study: 2014 objectives and design update.

Authors:  Albert Hofman; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2013-11-21       Impact factor: 8.082

4.  Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy.

Authors:  Kristine M Erlandson; Ying Jiang; Sara M Debanne; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2015-07-08       Impact factor: 9.079

5.  The Generation R Study: Biobank update 2015.

Authors:  Claudia J Kruithof; Marjolein N Kooijman; Cornelia M van Duijn; Oscar H Franco; Johan C de Jongste; Caroline C W Klaver; Johan P Mackenbach; Henriëtte A Moll; Hein Raat; Edmond H H M Rings; Fernando Rivadeneira; Eric A P Steegers; Henning Tiemeier; Andre G Uitterlinden; Frank C Verhulst; Eppo B Wolvius; Albert Hofman; Vincent W V Jaddoe
Journal:  Eur J Epidemiol       Date:  2014-12-21       Impact factor: 8.082

6.  Insulin Resistance and Markers of Inflammation in HIV-infected Ugandan Children in the CHAPAS-3 Trial.

Authors:  Sahera Dirajlal-Fargo; Victor Musiime; Adrian Cook; Grace Mirembe; Julia Kenny; Ying Jiang; Sara Debanne; Nigel Klein; Grace A McComsey
Journal:  Pediatr Infect Dis J       Date:  2017-08       Impact factor: 2.129

7.  New-onset type 2 diabetes mellitus among patients receiving HIV care at Newlands Clinic, Harare, Zimbabwe: retrospective cohort analysis.

Authors:  Cleophas Chimbetete; Catrina Mugglin; Tinei Shamu; Bindu Kalesan; Barbara Bertisch; Matthias Egger; Olivia Keiser
Journal:  Trop Med Int Health       Date:  2017-06-08       Impact factor: 2.622

Review 8.  Diabetes and HIV: current understanding and future perspectives.

Authors:  Sanjay Kalra; Navneet Agrawal
Journal:  Curr Diab Rep       Date:  2013-06       Impact factor: 4.810

9.  Microvascular Endothelial Dysfunction and Enhanced Thromboxane and Endothelial Contractility in Patients with HIV.

Authors:  Dan Wang; Joseph K Melancon; Jennifer Verbesey; Haihong Hu; Chenglong Liu; Shakil Aslam; Mary Young; Christopher S Wilcox
Journal:  J AIDS Clin Res       Date:  2013-12-01

Review 10.  Hypertension Is a Key Feature of the Metabolic Syndrome in Subjects Aging with HIV.

Authors:  Raquel Martin-Iguacel; Eugènia Negredo; Robert Peck; Nina Friis-Møller
Journal:  Curr Hypertens Rep       Date:  2016-06       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.